Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy

被引：0
|
作者：
Hiroki Ishihara
Toshio Takagi
Tsunenori Kondo
Hidekazu Tachibana
Kazuhiko Yoshida
Kenji Omae
Junpei Iizuka
Hirohito Kobayashi
Kazunari Tanabe
机构：
[1] Tokyo Women’s Medical University,Department of Urology, Kidney Center
[2] Tokyo Women’s Medical University Medical Center East,Department of Urology
[3] Kyoto University Graduate School of Medicine/School of Public Health,Department of Healthcare Epidemiology
[4] Fukushima Medical University,Center for Innovative Research for Communities and Clinical Excellence
来源：
International Journal of Clinical Oncology | 2018年 / 23卷
关键词：
Renal cell carcinoma; Targeted therapy; Third-line therapy; Tyrosine kinase inhibitor; mTORi; Metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：559 / 567
页数：8
相关论文
共 50 条
  • [21] Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
    Tanaka, Nobuyuki
    Mizuno, Ryuichi
    Shirotake, Suguru
    Ito, Keiichi
    Yasumizu, Yota
    Masunaga, Ayako
    Ito, Yujiro
    Miyazaki, Yasumasa
    Hagiwara, Masayuki
    Kanao, Kent
    Mikami, Shuji
    Nakagawa, Ken
    Momma, Tetsuo
    Masuda, Takeshi
    Asano, Tomohiko
    Oyama, Masafumi
    Oya, Mototsugu
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (07) : 293.e17 - 293.e25
  • [22] Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
    Korkmaz, Mustafa
    Eryilmaz, Melek K.
    Kocak, Mehmet Z.
    Er, Muhammed M.
    Hendem, Engin
    Demirkiran, Aykut
    Araz, Murat
    Karaagac, Mustafa
    Artac, Mehmet
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S160 - S165
  • [23] First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy
    Tannir, Nizar
    Hammers, Hans
    Amin, Asim
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 825 - 831
  • [24] Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
    Ishihara, Hiroki
    Kondo, Tsunenori
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Omae, Kenji
    Takagi, Toshio
    Iizuka, Junpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (12) : 1175 - 1181
  • [25] Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Fukuda, Hironori
    Tachibana, Hidekazu
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 705 - 712
  • [26] Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
    Hiroki Ishihara
    Toshio Takagi
    Tsunenori Kondo
    Hironori Fukuda
    Hidekazu Tachibana
    Kazuhiko Yoshida
    Junpei Iizuka
    Hirohito Kobayashi
    Masayoshi Okumi
    Hideki Ishida
    Kazunari Tanabe
    [J]. International Journal of Clinical Oncology, 2020, 25 : 705 - 712
  • [27] Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer
    Kongsted, Per
    Svane, Inge M.
    Lindberg, Henriette
    Bisbjerg, Rasmus
    Daugaard, Gedske
    Sengelov, Lisa
    [J]. ANTI-CANCER DRUGS, 2016, 27 (07) : 695 - 701
  • [28] First-line therapy for metastatic renal cell carcinoma
    Sawhney, Paramvir
    Suyanto, Suyanto
    Michael, Agnieszka
    Pandha, Hardev
    [J]. JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
  • [29] Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
    Busch, Jonas
    Seidel, Christoph
    Goranova, Irena
    Erber, Barbara
    Peters, Robert
    Friedersdorff, Frank
    Magheli, Ahmed
    Miller, Kurt
    Gruenwald, Viktor
    Weikert, Steffen
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (03) : 563 - 569
  • [30] A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma
    Heo, Ji Haeng
    Park, Chanhyun
    Ghosh, Somraj
    Park, Sun-Kyeong
    Zivkovic, Marko
    Rascati, Karen L.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (01) : 35 - 49
12345